Literature DB >> 20197411

Parkinson's disease-related LRRK2 G2019S mutation results from independent mutational events in humans.

Suzanne Lesage1, Etienne Patin, Christel Condroyer, Anne-Louise Leutenegger, Ebba Lohmann, Nir Giladi, Anat Bar-Shira, Soraya Belarbi, Nassima Hecham, Pierre Pollak, Anne-Marie Ouvrard-Hernandez, Soraya Bardien, Jonathan Carr, Traki Benhassine, Hiroyuki Tomiyama, Caroline Pirkevi, Tarik Hamadouche, Cécile Cazeneuve, A Nazli Basak, Nobutaka Hattori, Alexandra Dürr, Meriem Tazir, Avi Orr-Urtreger, Lluis Quintana-Murci, Alexis Brice.   

Abstract

Mutations in the leucine-rich-repeat kinase 2 (LRRK2) gene have been identified in families with autosomal dominant Parkinson's disease (PD) and in sporadic cases; the G2019S mutation is the single most frequent. Intriguingly, the frequency of this mutation in PD patients varies greatly among ethnic groups and geographic origins: it is present at <0.1% in East Asia, approximately 2% in European-descent patients and can reach frequencies of up to 15-40% in PD Ashkenazi Jews and North African Arabs. To ascertain the evolutionary dynamics of the G2019S mutation in different populations, we genotyped 74 markers spanning a 16 Mb genomic region around G2019S, in 191 individuals carrying the mutation from 126 families of different origins. Sixty-seven families were of North-African Arab origin, 18 were of North/Western European descent, 37 were of Jewish origin, mostly from Eastern Europe, one was from Japan, one from Turkey and two were of mixed origins. We found the G2019S mutation on three different haplotypes. Network analyses of the three carrier haplotypes showed that G2019S arose independently at least twice in humans. In addition, the population distribution of the intra-allelic diversity of the most widespread carrier haplotype, together with estimations of the age of G2019S determined by two different methods, suggests that one of the founding G2019S mutational events occurred in the Near East at least 4000 years ago.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20197411     DOI: 10.1093/hmg/ddq081

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  17 in total

Review 1.  The complex relationships between microglia, alpha-synuclein, and LRRK2 in Parkinson's disease.

Authors:  J Schapansky; J D Nardozzi; M J LaVoie
Journal:  Neuroscience       Date:  2014-10-02       Impact factor: 3.590

2.  LRRK2 G2019S mutation: frequency and haplotype data in South African Parkinson's disease patients.

Authors:  Soraya Bardien; Angelica Marsberg; Rowena Keyser; Debbie Lombard; Suzanne Lesage; Alexis Brice; Jonathan Carr
Journal:  J Neural Transm (Vienna)       Date:  2010-06-11       Impact factor: 3.575

3.  Deep phenotyping for precision medicine in Parkinson's disease.

Authors:  Ann-Kathrin Schalkamp; Nabila Rahman; Jimena Monzón-Sandoval; Cynthia Sandor
Journal:  Dis Model Mech       Date:  2022-06-01       Impact factor: 5.732

4.  Frequency of the LRRK2 G2019S mutation in South African patients with Parkinson's disease.

Authors:  Nicola du Toit; Riaan van Coller; David G Anderson; Jonathan Carr; Soraya Bardien
Journal:  Neurogenetics       Date:  2019-09-06       Impact factor: 2.660

5.  Genomic ancestry of North Africans supports back-to-Africa migrations.

Authors:  Brenna M Henn; Laura R Botigué; Simon Gravel; Wei Wang; Abra Brisbin; Jake K Byrnes; Karima Fadhlaoui-Zid; Pierre A Zalloua; Andres Moreno-Estrada; Jaume Bertranpetit; Carlos D Bustamante; David Comas
Journal:  PLoS Genet       Date:  2012-01-12       Impact factor: 5.917

6.  LRRK2 dephosphorylation increases its ubiquitination.

Authors:  Jing Zhao; Tyler P Molitor; J William Langston; R Jeremy Nichols
Journal:  Biochem J       Date:  2015-05-05       Impact factor: 3.857

7.  Variable frequency of LRRK2 variants in the Latin American research consortium on the genetics of Parkinson's disease (LARGE-PD), a case of ancestry.

Authors:  Mario Cornejo-Olivas; Luis Torres; Mario R Velit-Salazar; Miguel Inca-Martinez; Pilar Mazzetti; Carlos Cosentino; Federico Micheli; Claudia Perandones; Elena Dieguez; Victor Raggio; Vitor Tumas; Vanderci Borges; Henrique B Ferraz; Carlos R M Rieder; Artur Shumacher-Schuh; Carlos Velez-Pardo; Marlene Jimenez-Del-Rio; Francisco Lopera; Jorge Chang-Castello; Brennie Andreé-Munoz; Sarah Waldherr; Dora Yearout; Cyrus P Zabetian; Ignacio F Mata
Journal:  NPJ Parkinsons Dis       Date:  2017-06-02

8.  Clinical characterization of patients with leucine-rich repeat kinase 2 genetic variants in Japan.

Authors:  Yuanzhe Li; Aya Ikeda; Hiroyo Yoshino; Genko Oyama; Mitsuhiro Kitani; Kensuke Daida; Arisa Hayashida; Kotaro Ogaki; Kousuke Yoshida; Takashi Kimura; Yoshiaki Nakayama; Hidefumi Ito; Naoto Sugeno; Masashi Aoki; Hiroaki Miyajima; Katsuo Kimura; Naohisa Ueda; Masao Watanabe; Takao Urabe; Masashi Takanashi; Manabu Funayama; Kenya Nishioka; Nobutaka Hattori
Journal:  J Hum Genet       Date:  2020-05-13       Impact factor: 3.172

9.  LRRK2 kinase activity and biology are not uniformly predicted by its autophosphorylation and cellular phosphorylation site status.

Authors:  April Reynolds; Elizabeth A Doggett; Steve M Riddle; Connie S Lebakken; R Jeremy Nichols
Journal:  Front Mol Neurosci       Date:  2014-06-24       Impact factor: 5.639

10.  Evidence for prehistoric origins of the G2019S mutation in the North African Berber population.

Authors:  Rafiqua Ben El Haj; Ayyoub Salmi; Wafa Regragui; Ahmed Moussa; Naima Bouslam; Houyam Tibar; Ali Benomar; Mohamed Yahyaoui; Ahmed Bouhouche
Journal:  PLoS One       Date:  2017-07-19       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.